Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Guggenheim

Keros Therapeutics (NASDAQ:KROS - Get Free Report)'s stock had its "neutral" rating restated by analysts at Guggenheim in a report released on Friday,Benzinga reports.

A number of other analysts also recently issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. BTIG Research lowered Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, December 12th. Oppenheimer dropped their price objective on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research note on Thursday. Wedbush reissued an "outperform" rating and set a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Wells Fargo & Company upped their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $52.56.

Keros Therapeutics Stock Performance

NASDAQ KROS traded up $0.34 during trading on Friday, hitting $10.86. The stock had a trading volume of 2,986,409 shares, compared to its average volume of 1,205,141. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The company's 50-day moving average price is $36.37 and its two-hundred day moving average price is $47.13. The company has a market capitalization of $439.94 million, a PE ratio of -2.08 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm's quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.33) earnings per share. As a group, equities analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. KBC Group NV grew its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the second quarter valued at about $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics during the third quarter worth about $213,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.